Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
- PMID: 12821247
- DOI: 10.1016/s0735-1097(03)00464-9
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
Abstract
The purpose of the present study was to evaluate the effect of angiotensin II type 1 receptor (AT1R) antagonist on chronic structural remodeling in atrial fibrillation (AF).
Background: We previously reported that an AT1R antagonist, candesartan, prevents acute electrical remodeling in a rapid pacing model. However, the effect of candesartan on chronic structural remodeling in AF is unclear.
Methods: Sustained AF was induced in 20 dogs (10 in a control group and 10 in a candesartan group) by rapid pacing of the right atrium (RA) at 400 beats/min for five weeks. Candesartan was administered orally (10 mg/kg/day) for one week before rapid pacing and was continued for five weeks. The AF duration, atrial effective refractory period (AERP) at four sites in the RA, and intra-atrial conduction time (CT) from the RA appendage to the other three sites were measured every week.
Results: The mean AF duration in the control group after five weeks was significantly longer than that with candesartan (1,333 +/- 725 vs. 411 +/- 301 s, p < 0.01). The degree of AERP shortening after five weeks was not significantly different between the two groups. The CT from the RA appendage to the low RA after five weeks with candesartan was significantly shorter than that in the control (43 +/- 14 vs. 68 +/- 10 ms, p < 0.05). The candesartan group had a significantly lower percentage of interstitial fibrosis than the control group (7 +/- 2% vs. 16 +/- 1% at the RA appendage, p < 0.001).
Conclusions: Candesartan can prevent the promotion of AF by suppressing the development of structural remodeling.
Comment in
-
Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation?J Am Coll Cardiol. 2003 Jun 18;41(12):2205-6. doi: 10.1016/s0735-1097(03)00469-8. J Am Coll Cardiol. 2003. PMID: 12821248 No abstract available.
Similar articles
-
Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation.Circulation. 2000 Jun 6;101(22):2612-7. doi: 10.1161/01.cir.101.22.2612. Circulation. 2000. PMID: 10840013
-
Effects of Cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogs.J Electrocardiol. 2007 Jan;40(1):100.e1-6. doi: 10.1016/j.jelectrocard.2006.04.001. Epub 2006 Oct 25. J Electrocardiol. 2007. PMID: 17067622
-
Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation?J Am Coll Cardiol. 2003 Jun 18;41(12):2205-6. doi: 10.1016/s0735-1097(03)00469-8. J Am Coll Cardiol. 2003. PMID: 12821248 No abstract available.
-
Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model.Circ J. 2007 Dec;71(12):1977-82. doi: 10.1253/circj.71.1977. Circ J. 2007. PMID: 18037757
-
[New approach for atrial fibrillation by suppression of renin-angiotensin system].Nihon Rinsho. 2005 Mar;63(3):523-7. Nihon Rinsho. 2005. PMID: 15773355 Review. Japanese.
Cited by
-
[Basic mechanisms of the new antiarrhythmic drugs in atrial fibrillation].Arch Cardiol Mex. 2012 Apr-Jun;82(2):139-52. Arch Cardiol Mex. 2012. PMID: 22735655 Free PMC article. Review. Spanish.
-
Atrial overexpression of angiotensin-converting enzyme 2 improves the canine rapid atrial pacing-induced structural and electrical remodeling. Fan, ACE2 improves atrial substrate remodeling.Basic Res Cardiol. 2015;110(4):45. doi: 10.1007/s00395-015-0499-0. Epub 2015 Jul 5. Basic Res Cardiol. 2015. PMID: 26143546 Free PMC article.
-
PU.1 inhibition attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II by reducing TGF-β1/Smads pathway activation.J Cell Mol Med. 2021 Jul;25(14):6746-6759. doi: 10.1111/jcmm.16678. Epub 2021 Jun 15. J Cell Mol Med. 2021. PMID: 34132026 Free PMC article.
-
The Role of the Rho/ROCK Pathway in Ang II and TGF-β1-Induced Atrial Remodeling.PLoS One. 2016 Sep 9;11(9):e0161625. doi: 10.1371/journal.pone.0161625. eCollection 2016. PLoS One. 2016. PMID: 27611832 Free PMC article.
-
Recent advances in pharmacotherapy of atrial fibrillation.Indian J Pharmacol. 2009 Aug;41(4):153-7. doi: 10.4103/0253-7613.56064. Indian J Pharmacol. 2009. PMID: 20523864 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical